Recently, a similar approach has been proposed for prostate cancer, and it has been demonstrated that, in prostate cellular models, celecoxib reduces cell growth, induces apoptosis, and promotes EGFR degradation. This evidence concerns the gene EGFR and prostate carcinoma.